CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 100 target
Drug / intervention
No Intervention: Observational Cohortother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07303218
NCT07303218N/AActiveOn TrackUpdated 6mo ago
CompareCT.gov

The HER Project: Homologous Recombination Deficiency in EGFR-Mutated NSCLC, a Retrospective and Prospective Translational Single-center Study

IRCCS San Raffaele·observational·Posted Dec 24, 2025·Updated Dec 31, 2025

In Brief

An observational study evaluating No Intervention: Observational Cohort for EGFR and 3 related conditions. Active but no longer recruiting, targeting 100 participants across 1 site.

Detailed Summary

This observational retrospective-prospective study aims to evaluate the prevalence of homologous recombination deficiency (HRD) in metastatic EGFR mutated NSCLC and to assess its correlation with clinical and molecular features. Based on the hypothesis that HRD identifies a distinct EGFRm subgroup with prognostic value and a potential sensitivity to PARP inhibitor-based strategies, translational analysis will be performed with multiple pre-clinical models, ranging from human cancer cells to murine models.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEGFR, Non Small Cell Lung Cancer, Homologous Recombination Deficiency, PARP Inhibitor
CountriesItaly
Collaborators--

Timeline

N/AActive
20262027202820292030203120322033
First PostedDec 24, 2025
Enrollment StartDec 1, 2025
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2032
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 6 months agoPrimary completion in 3.5 years

Interventions

No Intervention: Observational Cohortother

Observational study only; participants receive standard-of-care treatments not assigned by the study